title: Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency.
abstract: 5-Fluorouracil (5-FU) is rapidly degraded by dihyropyrimidine dehydrogenase (DPD). Therefore, DPD deficiency can lead to severe toxicity or even death following treatment with 5-FU or capecitabine. Different tests based on assessing DPD enzyme activity, genetic variants in DPYD and mRNA variants have been studied for screening for DPD deficiency, but none of these are implemented broadly into clinical practice. We give an overview of the tests that can be used to detect DPD deficiency and discuss the advantages and disadvantages of these tests.
authors.affiliation: Department of Pharmacy, Scheper Hospital Emmen and Röpcke Zweers Hospital Hardenberg, Emmen, The Netherlands.
authors.forename: M C
authors.initials: MC
authors.lastname: van Staveren
authors.forename: H Jan
authors.initials: HJ
authors.lastname: Guchelaar
authors.forename: A B P
authors.initials: AB
authors.lastname: van Kuilenburg
authors.forename: H
authors.initials: H
authors.lastname: Gelderblom
authors.forename: J G
authors.initials: JG
authors.lastname: Maring
mesh_terms: D000818:Animals; D054067:Dihydropyrimidine Dehydrogenase Deficiency / Q000175:diagnosis* / Q000201:enzymology / Q000235:genetics; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000032:analysis* / Q000235:genetics / Q000378:metabolism; D005820:Genetic Testing / Q000379:methods*; D006801:Humans
chemical_list: D042943:Dihydrouracil Dehydrogenase (NADP)